Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Sipos

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
JAMA Otolaryngology-- Head & Neck Surgery|December 23, 2020
Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer RecurrenceKevin J Kovatch, David Reyes-Gastelum, Jennifer A Sipos, et al.
The Journal of Clinical Endocrinology and Metabolism|February 28, 2024
Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI NodulesMayumi Endo, Jing Peng, Fadi A Nabhan, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 2024
Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent StudiesMario Rotondi, Mayumi Endo, Marsida Teliti, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIERJennifer A Sipos, Thomas C Blevins, Heidi Chamberlain Shea, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 28, 2024
Defining the Functional Sensitivity for the Siemens Atellica Calcitonin Assay: Insight From a Single-Center StudyJieli Li, Ashley Patton, Jason K Y Lee, et al.
Cancer Medicine|January 15, 2021
Prevalence of cancer and the benign call rate of afirma gene classifier in <sup>18</sup> F-Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodulesMayumi Endo, Jennifer A Sipos, Matthew D Ringel, et al.
Journal of the Endocrine Society|August 11, 2023
Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid CancerJennifer A Sipos, Joseph Aloi, Andrew Gianoukakis, et al.
Clinical Chemistry|July 9, 2017
United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for CalcitoninGeorge J Kahaly, Alicia Algeciras-Schimnich, Thomas E Davis, et al.
Thyroid : Official Journal of the American Thyroid Association|June 4, 2019
Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid NodulesMayumi Endo, Fadi Nabhan, Kyle Porter, et al.
Oncotarget|December 22, 2017
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O<sup>6</sup>-methylguanine DNA methyltransferase as a biomarker for responseDwight H Owen, Andrew J Alexander, Bhavana Konda, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
JAMA Otolaryngology-- Head & Neck Surgery|December 23, 2020
Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer RecurrenceKevin J Kovatch, David Reyes-Gastelum, Jennifer A Sipos, et al.
The Journal of Clinical Endocrinology and Metabolism|February 28, 2024
Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI NodulesMayumi Endo, Jing Peng, Fadi A Nabhan, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 2024
Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent StudiesMario Rotondi, Mayumi Endo, Marsida Teliti, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIERJennifer A Sipos, Thomas C Blevins, Heidi Chamberlain Shea, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 28, 2024
Defining the Functional Sensitivity for the Siemens Atellica Calcitonin Assay: Insight From a Single-Center StudyJieli Li, Ashley Patton, Jason K Y Lee, et al.
Cancer Medicine|January 15, 2021
Prevalence of cancer and the benign call rate of afirma gene classifier in <sup>18</sup> F-Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodulesMayumi Endo, Jennifer A Sipos, Matthew D Ringel, et al.
Journal of the Endocrine Society|August 11, 2023
Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid CancerJennifer A Sipos, Joseph Aloi, Andrew Gianoukakis, et al.
Clinical Chemistry|July 9, 2017
United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for CalcitoninGeorge J Kahaly, Alicia Algeciras-Schimnich, Thomas E Davis, et al.
Thyroid : Official Journal of the American Thyroid Association|June 4, 2019
Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid NodulesMayumi Endo, Fadi Nabhan, Kyle Porter, et al.
Oncotarget|December 22, 2017
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O<sup>6</sup>-methylguanine DNA methyltransferase as a biomarker for responseDwight H Owen, Andrew J Alexander, Bhavana Konda, et al.
Pageof 4